Recall alert: Stop putting your baby in these nests and loungers now, warns Health Canada
Health Canada has recalled a wide range of portable beds for infants because they pose a risk of smothering, entrapment or falls.
Article content
The products known as baby nests or loungers have soft, padded sides and are advertised as multi-functional products that can be used as a sleep surface, changing mat and tummy time mat.
Article content
Article content
Article content
Article content
Article content
Anyone with one of the above products should immediately stop using it. Health Canada said no nest or lounger is safe for sleep because of a suffocation risk, and no infant should be left unattended in one.
Article content
The products should never be placed inside another device like a crib, cradle, bassinet or playpen. Nor should they go on a bed, waterbed, air mattress, couch, futon or armchair, because the suffocation risk is greater on soft, uneven surfaces.
Article content
Even if you bought a baby nest or lounger not listed in the recall, 'Health Canada advises that it not be used as a sleep surface,' said the notice. 'Consumers are reminded that the safest place for a baby to sleep is alone on a firm, flat surface.'
Article content
Article content
Article content
Though Health Canada is not aware of any injuries related to the products in Canada, there have been 'continued incidents and concerns related to baby nests/loungers across North America,' and is reminding consumers that the products pose a risk.
Article content
Article content
In the U.S. between 2021 and 2023, the U.S. Consumer Product Safety Commission received 45 reports of incidents involving baby nests and loungers, 29 of which resulted in deaths.
Article content
Health Canada is currently sampling and evaluating all baby nests and loungers to determine their safety. Meanwhile, the listed brands have been recalled and removed from market because they don't meet Canadian safety standards.
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
44 minutes ago
- Cision Canada
Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance Français
Eligible Canadian patients with heterozygous familial hypercholesterolemia (HeFH) are one step closer to publicly funded access to cholesterol lowering treatment. MONTRÉAL, Aug. 21, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of Leqvio ® (inclisiran) for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH), a genetic condition characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C), significantly increasing the risk of early cardiovascular events such as heart attack and stroke. 1 "At HeartLife, we believe that people living with FH deserve timely access to the most effective therapies available," said Marc Bains, Co-Founder, HeartLife Foundation. "This agreement is an important step forward in closing long-standing gaps in care and expanding treatment options for patients who face a significantly higher risk of early heart disease. We are committed to working with partners across Canada to ensure these advances reach the people who need them most." "Familial Hypercholesterolemia is underdiagnosed and undertreated, despite the significant cardiovascular risk it carries," said Dr. Liam Brunham, Canada Research Chair and Associate Professor at University of British Columbia and Co-Lead of FH Canada. "For many patients with FH, it is challenging to control LDL-C levels with standard therapies. Having access to advanced therapies is an important advance in the treatment of these patients. The conclusion of pCPA negotiations for this therapy is a positive sign towards expanded access to treatment options and closing an important gap in care." "Concluding pCPA negotiations for Leqvio ® is a significant moment for Canadians living with HeFH," said Mark Vineis, Country President, Novartis Pharmaceuticals Canada Inc. "We're committed to working with provincial and territorial partners to help ensure timely and equitable access to this treatment option for patients with elevated cardiovascular risk." Although this milestone represents meaningful progress, public reimbursement through provincial and territorial formularies has not yet been secured. As the next step, Novartis will collaborate with public drug programs towards timely access to treatment for eligible patients living with HeFH. About Leqvio ® (inclisiran) Leqvio ® is indicated as an adjunct to lifestyle changes, including diet, to further reduce LDL-C level in adults living with HeFH who are on maximally tolerated dose of a statin, with or without other LDL-C-lowering therapies. Leqvio ® was first approved by Health Canada in 2021 based on clinical trials that demonstrated its efficacy to safely lower LDL cholesterol 2,3,4 and received a positive funding recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) in 2021 for adults with HeFH. Since its commercialization in 2022, Leqvio ® has made a difference in the lives of more than 4,500 Canadians and 290,000 patients worldwide. 5 About Cardiovascular Disease (CVD) Cardiovascular diseases (CVD), including heart disease, stroke and vascular cognitive impairment, are responsible for the loss of one life every five minutes, 6 and are the second leading cause of death in Canada after cancer. 7 In Canada, heart disease is the leading cause of hospitalization among Canadian women, aside from giving birth, 8 and within the Canadian healthcare system, CVD accounts for $22 billion annually. 5 The five-year prevalence of ASCVD in Canada ranges between 6.91%-8.55% in adults. 6, 7 HeFH has an estimated prevalence of 1 in 250 to 311 individuals. 9,10,11 About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit FA-11492432E SOURCE Novartis Pharmaceuticals Canada Inc.
Cision Canada
2 hours ago
- Cision Canada
Canadian Brand Red Dog Blue Kat Launches Everyday Raw Anywhere, a First of Its Kind Shelf Stable Raw Pet Food
VANCOUVER, B.C., Aug. 20, 2025 /CNW/ - Pet parents who love feeding raw but want something easier for busy lives or travel now have a new option. Red Dog Blue Kat is introducing Everyday Raw Anywhere, a shelf stable raw food for dogs that keeps 95 percent of essential nutrients and reduces carbon emissions by 75 percent compared with freeze drying. It brings the nutrition of raw with the ease of dry. No freezer needed. Everyday Raw Anywhere is the first shelf stable raw pet food made in Canada with GentleDry™ Technology. Post this Everyday Raw Anywhere is powered by GentleDry™ Technology developed in British Columbia. The process uses a low temperature, 90 minute cycle that combines microwave and infrared energy inside a controlled vacuum environment. Moisture is removed quickly and evenly, so food spends less time under heat. This gentle approach protects vitamins, flavour, colour, and aroma to keep nutrition close to fresh raw. Other shelf stable raw alternatives, such as air dried and dehydrated foods, can lose up to 40 percent of heat sensitive nutrients and often require more energy intensive drying. "Innovation is at the heart of RDBK," said Inna Shekhtman, founder of RDBK. "We found a game changing technology built by engineers and researchers from the UBC entrepreneurship community and adapted it for raw pet food so families can serve real nutrition in a way that fits busy routines and active adventures." Designed for real life on the go, you can feed it three ways: Complete and balanced meal. Add water, stir, and serve in about five minutes. Premium topper. Mix into kibble, canned, or raw for an easy bowl booster. High value treat. Serve dry for training. Pets and their people are already giving it great reviews. In a blind consumer study with 50 dog parents, 98 percent praised the smell, appearance, and texture, 92 percent of dogs ate eagerly, and 76 percent said rehydration was quick and complete. Canadian pet parent Julia C., a full time nurse who hikes and camps with her dogs, added, "My dogs' health is incredibly important to me. Feeding them something nutritious, good for the planet, and as close to fresh raw as possible gives me real peace of mind. Everyday Raw Anywhere has surpassed my expectations for a shelf stable food." Sustainability matters to today's families. Everyday Raw Anywhere is made in British Columbia with responsibly sourced ingredients, the majority from Canadian farms, supporting local agriculture and reducing transportation impact. Its lighter shipping weight and no refrigeration format further reduce the footprint from plant to bowl. The packaging celebrates Canadian heritage with hand drawn illustrations inspired by the country's landscapes and outdoor adventures. It reflects Red Dog Blue Kat's long standing support for local farmers, independent pet retailers, and homegrown innovation.
Toronto Star
4 hours ago
- Toronto Star
When it comes to marketing alcohol to teens, the fox has been left guarding the henhouse
'Over 1-in-3 Canadian teens report drinking in the past 12 months and they take that first drink at an average age of 13,' writes Iris Gorfinkel. dreamstime Opinion articles are based on the author's interpretations and judgments of facts, data and events. More details
